CN104918959A - 包含至少两个针对her2的重复序列结构域的结合蛋白 - Google Patents

包含至少两个针对her2的重复序列结构域的结合蛋白 Download PDF

Info

Publication number
CN104918959A
CN104918959A CN201380062520.9A CN201380062520A CN104918959A CN 104918959 A CN104918959 A CN 104918959A CN 201380062520 A CN201380062520 A CN 201380062520A CN 104918959 A CN104918959 A CN 104918959A
Authority
CN
China
Prior art keywords
her2
seq
repeat
domain
structural domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380062520.9A
Other languages
English (en)
Chinese (zh)
Inventor
乌尔丽克·菲德勒
伊格纳西奥·多拉多
海克·施特罗贝尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Partners AG
Original Assignee
Molecular Partners AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Molecular Partners AG filed Critical Molecular Partners AG
Publication of CN104918959A publication Critical patent/CN104918959A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cell Biology (AREA)
CN201380062520.9A 2012-11-30 2013-12-02 包含至少两个针对her2的重复序列结构域的结合蛋白 Pending CN104918959A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12195156.0 2012-11-30
EP12195156.0A EP2738180A1 (en) 2012-11-30 2012-11-30 Binding proteins comprising at least two binding domains against HER2.
PCT/EP2013/075290 WO2014083208A1 (en) 2012-11-30 2013-12-02 Binding proteins comprising at least two repeat domains against her2

Publications (1)

Publication Number Publication Date
CN104918959A true CN104918959A (zh) 2015-09-16

Family

ID=47257683

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380062520.9A Pending CN104918959A (zh) 2012-11-30 2013-12-02 包含至少两个针对her2的重复序列结构域的结合蛋白

Country Status (11)

Country Link
US (1) US10370414B2 (https=)
EP (2) EP2738180A1 (https=)
JP (1) JP6410724B2 (https=)
KR (1) KR102290592B1 (https=)
CN (1) CN104918959A (https=)
AU (2) AU2013351096C9 (https=)
CA (1) CA2892747C (https=)
HK (1) HK1211297A1 (https=)
MX (1) MX366223B (https=)
RU (1) RU2664464C9 (https=)
WO (1) WO2014083208A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109790206A (zh) * 2016-09-22 2019-05-21 分子组合公司 重组结合蛋白及其用途
CN114269366A (zh) * 2019-06-04 2022-04-01 分子伴侣公司 重组fap结合蛋白及其用途

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
DK2643349T3 (da) * 2010-11-26 2019-11-25 Molecular Partners Ag Designede repeat-proteiner, der binder til serumalbumin
CA2883264A1 (en) * 2012-10-15 2014-04-24 Universitat Zurich Prorektorat Mnw Bispecific her2 ligands for cancer therapy
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor
HRP20250551T1 (hr) 2013-11-27 2025-06-20 Zymeworks Bc Inc. Bispecifični antigen-vezujući konstrukti koji ciljaju her2
EP3223848B1 (en) 2014-11-27 2024-11-27 Zymeworks BC Inc. Methods of using bispecific antigen-binding constructs targeting her2
JP6738340B2 (ja) 2015-02-06 2020-08-12 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 新規なｅｇｆｒ結合タンパク質
AU2016240220B2 (en) 2015-04-02 2019-11-21 Molecular Partners Ag Designed ankyrin repeat domains with binding specificity for serum albumin
AU2016293063B2 (en) 2015-07-16 2018-11-08 Navigo Proteins Gmbh Novel immunoglobulin-binding proteins and their use in affinity purification
DK3325514T3 (da) * 2015-07-20 2019-12-16 Navigo Proteins Gmbh Her2-bindende proteiner baseret på di-ubiquitin-muteiner
JP2018520675A (ja) * 2015-07-20 2018-08-02 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
EP3452097A1 (en) 2016-05-04 2019-03-13 Navigo Proteins GmbH Targeted compounds for the site-specific coupling of chemical moieties comprising a peptide linker
RU2627215C1 (ru) * 2016-05-24 2017-08-03 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Нижегородский государственный университет им. Н.И. Лобачевского" Рекомбинантный таргетный токсин, специфичный к клеткам, экспрессирующим рецептор her2
SG11201901066UA (en) 2016-08-11 2019-03-28 Navigo Proteins Gmbh Novel alkaline stable immunoglobulin-binding proteins
CN110352068A (zh) 2016-12-02 2019-10-18 南加利福尼亚大学 合成的免疫受体及其使用方法
WO2019091918A1 (en) 2017-11-07 2019-05-16 Navigo Proteins Gmbh Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
MA54501A (fr) 2018-12-18 2021-10-27 Navigo Proteins Gmbh Nouvelles protéines de liaison spécifiques de folr1 pour le diagnostic et le traitement du cancer
CN114206943A (zh) 2019-06-04 2022-03-18 分子伴侣公司 多特异性蛋白质
US12441772B2 (en) 2019-06-04 2025-10-14 Molecular Partners Ag Designed ankyrin repeat domain with improved stability
EP3980452A1 (en) * 2019-06-04 2022-04-13 Molecular Partners AG Recombinant 4-1bb binding proteins and their use
US12240913B2 (en) 2019-07-26 2025-03-04 Abl Bio Inc. Anti-HER2/anti-4-1BB bispecific antibody and use thereof
KR20220113492A (ko) 2019-12-11 2022-08-12 몰리큘라 파트너스 아게 변경된 표면 잔기를 갖는 설계된 안키린 반복 도메인
KR20230006558A (ko) 2020-05-06 2023-01-10 몰리큘라 파트너스 아게 신규한 안키린 반복 결합 단백질 및 그의 용도
IL298168A (en) 2020-05-14 2023-01-01 Molecular Partners Ag Multispecific proteins
US20240279309A1 (en) * 2020-05-14 2024-08-22 Molecular Partners Ag Recombinant cd40 binding proteins and their use
CA3202358A1 (en) 2020-12-16 2022-06-23 Andreas BOSSHART Novel slow-release prodrugs
AU2022233791A1 (en) 2021-03-09 2023-09-28 Molecular Partners Ag Novel darpin based cd123 engagers
JP2024509890A (ja) 2021-03-09 2024-03-05 モレキュラー パートナーズ アクチェンゲゼルシャフト プロテアーゼ切断可能なプロドラッグ
WO2022190010A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd33 engagers
IL305677A (en) 2021-03-09 2023-11-01 Molecular Partners Ag Novel darpin based multi-specific t-cell engagers
IL313411A (en) 2021-12-14 2024-08-01 Molecular Partners Ag Designed repeat domains with dual binding specificity and their use
JP2025527242A (ja) * 2022-08-01 2025-08-20 モレキュラー パートナーズ アクチェンゲゼルシャフト 電荷改変され設計された反復ドメイン及びそれらの使用
WO2024038307A1 (en) 2022-08-19 2024-02-22 Novartis Ag Dosing regimens for sars-cov-2 binding molecules
EP4673159A1 (en) 2023-02-27 2026-01-07 Molecular Partners AG Darpins for use in reducing renal accumulation of drugs
WO2024251628A1 (en) 2023-06-06 2024-12-12 Molecular Partners Ag Recombinant cd16a binding proteins and their use
WO2025146491A1 (en) 2024-01-05 2025-07-10 Molecular Partners Ag Designed repeat domains with dual binding specificity for cd117 and cd47-binding agent

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997382A (zh) * 2004-05-05 2007-07-11 梅里麦克制药股份有限公司 调节生物活性的双特异性结合剂
WO2009068625A2 (en) * 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
WO2011054519A1 (en) * 2009-11-05 2011-05-12 F. Hoffmann-La Roche Ag Glycosylated repeat-motif-molecule conjugates
WO2012162418A1 (en) * 2011-05-23 2012-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for heterodimeric targeting ligands

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
DE69834032T2 (de) 1997-04-23 2006-12-07 Universität Zürich Verfahren zur erkennung von nucleinsäuremolekülen codierend für (poly)peptide, welche mit zielmolekülen interagieren
DE69935248T2 (de) 1998-12-02 2007-11-08 Adnexus Therapeutics, Inc., Waltham Dna-protein fusionen sowie anwendungen derselben
DE60140474D1 (de) 2000-09-08 2009-12-24 Univ Zuerich Sammlung von proteinen mit sich wiederholenden sequenzen (repeat proteins), die repetitive sequenzmodule enthalten
KR20140032004A (ko) * 2004-07-22 2014-03-13 제넨테크, 인크. Ｈｅｒ２ 항체 조성물
BRPI0613593A2 (pt) 2005-07-08 2011-01-18 Univ Zuerich método de teste "phage display" filamentoso, vetor de fago ou de fagomìdeo e biblioteca de vetores de fago ou fagomìdeo
EP1996937A4 (en) 2006-03-06 2009-04-08 Amunix Inc GENETIC PACKS AND USES THEREOF
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
CA2700391A1 (en) 2007-09-24 2009-04-02 University Of Zuerich Designed armadillo repeat proteins
US20100260668A1 (en) * 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP3785735A1 (en) 2008-11-03 2021-03-03 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
DK2643349T3 (da) 2010-11-26 2019-11-25 Molecular Partners Ag Designede repeat-proteiner, der binder til serumalbumin
EP2702069A4 (en) 2011-04-29 2015-04-29 Janssen Biotech Inc IL4 / IL13 BINDING REPEAT PROTEINS AND USES THEREOF
CA2877584A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
CA2883264A1 (en) 2012-10-15 2014-04-24 Universitat Zurich Prorektorat Mnw Bispecific her2 ligands for cancer therapy
US11453708B2 (en) 2013-05-31 2022-09-27 Molecular Partners Ag Designed ankyrin repeat proteins binding to hepatocyte growth factor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997382A (zh) * 2004-05-05 2007-07-11 梅里麦克制药股份有限公司 调节生物活性的双特异性结合剂
WO2009068625A2 (en) * 2007-11-27 2009-06-04 Ablynx N.V. Amino acid sequences directed against her2 and polypeptides comprising the same for the treatment of cancers and/or tumors
WO2011054519A1 (en) * 2009-11-05 2011-05-12 F. Hoffmann-La Roche Ag Glycosylated repeat-motif-molecule conjugates
WO2012162418A1 (en) * 2011-05-23 2012-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for heterodimeric targeting ligands

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHRISTIAN ZAHND等: "A Designed Ankyrin Repeat Protein Evolved to Picomolar Affinity to HER2", 《JOURNAL OF MOLECULAR BIOLOGY》 *
ULRIK B. NIELSEN等: "Targeting of Bivalent Anti-ErbB2 Diabody Antibody Fragments to Tumor Cells Is Independent of the intrinsic antibody Affinity", 《CANCER RESEARCH》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109790206A (zh) * 2016-09-22 2019-05-21 分子组合公司 重组结合蛋白及其用途
CN114269366A (zh) * 2019-06-04 2022-04-01 分子伴侣公司 重组fap结合蛋白及其用途

Also Published As

Publication number Publication date
MX366223B (es) 2019-07-03
AU2013351096C1 (en) 2018-11-08
CA2892747C (en) 2022-07-19
AU2018256592A1 (en) 2018-11-22
RU2664464C2 (ru) 2018-08-17
US10370414B2 (en) 2019-08-06
JP6410724B2 (ja) 2018-10-24
HK1211297A1 (zh) 2016-05-20
EP2925784A1 (en) 2015-10-07
WO2014083208A8 (en) 2014-10-30
JP2015537044A (ja) 2015-12-24
EP2925784B1 (en) 2021-02-17
AU2013351096B2 (en) 2018-08-09
RU2015120663A (ru) 2017-01-10
US20150299265A1 (en) 2015-10-22
WO2014083208A9 (en) 2014-12-24
MX2015006548A (es) 2015-10-15
AU2013351096A1 (en) 2015-07-09
BR112015012436A2 (pt) 2017-09-12
KR102290592B1 (ko) 2021-08-19
AU2013351096C9 (en) 2019-01-31
RU2664464C9 (ru) 2018-12-19
WO2014083208A1 (en) 2014-06-05
EP2738180A1 (en) 2014-06-04
KR20150091138A (ko) 2015-08-07
CA2892747A1 (en) 2014-06-05

Similar Documents

Publication Publication Date Title
KR102290592B1 (ko) Her2에 대항하는 적어도 두 개 이상의 반복 도메인을 포함하는 결합 단백질
JP6976335B2 (ja) 組み換え結合タンパク質及びその使用
WO2019174603A1 (zh) 靶向ctla-4抗体、其制备方法和用途
US20220298212A1 (en) Recombinant 4-1bb binding proteins and their use
US20250074994A1 (en) Novel darpin based cd70 engagers
CA3178478A1 (en) Recombinant cd40 binding proteins and their use
US20240317852A1 (en) Novel darpin based cd33 engagers
CN105026422B (zh) Sh2结构域变体
JP2024509241A (ja) 新規のＤＡＲＰｉｎに基づくＣＤ１２３エンゲージャ
JP2023554379A (ja) 組換えｃｄ３結合タンパク質及びそれらの使用
CN114945584A (zh) 重组肽-mhc复合物结合蛋白及其生成和用途
KR20210075080A (ko) Her2-결합 사량체 폴리펩티드
BR112015012436B1 (pt) Proteína de ligação recombinante e formulação farmacêutica
CN117242100A (zh) 基于DARPin的新型CD70接合物
RU2778346C2 (ru) Рекомбинантные связывающие белки и их применение
AU2024286934A1 (en) Recombinant cd2 binding proteins and their use
CN117255803A (zh) 基于DARPin的新型CD33接合物
CN116802213A (zh) 重组cd3结合蛋白及其用途
CN117177996A (zh) 基于DARPin的新型CD123接合物

Legal Events

Date Code Title Description
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1211297

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20150916

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1211297

Country of ref document: HK